Safety, Tolerability, and Efficacy of Daclatasvir and Asunaprevir, With or Without BMS-791325, in Subjects Coinfected With HIV-HCV
Phase of Trial: Phase II
Latest Information Update: 18 May 2017
Price : $35 *
At a glance
- Drugs Asunaprevir (Primary) ; Daclatasvir (Primary) ; Beclabuvir
- Indications Hepatitis C
- Focus Therapeutic Use
- 17 Nov 2016 Status changed from active, no longer recruiting to completed.
- 17 Apr 2016 Results (n=30) presented at The International Liver Congress™ 2016
- 08 Dec 2015 Planned primary completion date changed from 1 Jan 2016 to 1 Nov 2016 as reported by ClinicalTrials.gov record.